Fierce 15 2003

Most Promising Biotechs of 2003


Welcome to The Fierce 15, the top emerging biotech

and medical device companies of 2003. Every year FierceBiotech evaluates hundreds of company to unearth firms with the vision and management expertise to change how doctors treat disease or technology to improve the drug development process.

This year’s Fierce 15 all combined strong commercial and financial partnerships with nimble executive decisions to successfully navigate the biotech malaise of 2002. As the shakeout deepens, we expect these companies to emerge as leaders of next decade.

You will not find the big guys among The Fierce 15. No Mercks or Pfizers. The Fierce 15 include the rising stars of medical devices and biotech -- private companies that may not be on your radar now, but should be.

Ignore them at your peril.

And the winners are...


Suggested Articles

As Relay looks to enter the clinic in 2020, the company is adding a trio of biopharma vets to its leadership team.

A phase 3 trial of Myovant Sciences’ relugolix in prostate cancer has met its primary endpoint, teeing the company up to file for FDA approval.

The Medicines Company, fresh from its turn at the AHA this weekend, has seen its shares jump on growing rumors that Novartis wants to acquire it.